US equities
|
MU
$983.23
▲+5.86%
META
$612.49
▼-1.24%
GOOGL
$324.89
▲+1.34%
NVDA
$215.38
▼-1.17%
MSFT
$531.01
▼-0.06%
TSLA
$404.22
▼-0.80%
SPCX
$145.23
▼-2.25%
SNDK
$1,404.77
▲+7.66%
MU
$983.23
▲+5.86%
META
$612.49
▼-1.24%
GOOGL
$324.89
▲+1.34%
NVDA
$215.38
▼-1.17%
MSFT
$531.01
▼-0.06%
TSLA
$404.22
▼-0.80%
SPCX
$145.23
▼-2.25%
SNDK
$1,404.77
▲+7.66%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Haemonetics Corporation Common Stock
(NY:
HAE
)
118.32
-1.65 (-1.38%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Haemonetics Corporation Common Stock
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
September 15, 2026
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
January 12, 2026
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
September 24, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Haemonetics Corp. (NYSE: HAE) Making Surprising Moves in Monday Session
July 17, 2023
Via
Investor Brand Network
Watch for Continued Gains in Shares of Haemonetics Corporation (HAE)
September 12, 2022
Via
Investor Brand Network
Sotera Health Appoints Christopher Simon to the Board of Directors
August 01, 2024
From
Sotera Health Services, LLC
Via
GlobeNewswire
How 2022's Biggest Healthcare Gainers Could Fare In 2023
January 06, 2023
Health care stocks were hit hard early in the pandemic but these three have made quite a comeback. This article examines where they could go in 2023
Via
MarketBeat